Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Trobalt

- PMLiVE

Shionogi scores FDA approval for new cUTI antibiotic

Pivotal new treatment for adults with complicated urinary tract infection

- PMLiVE

GSK boosts outlook thanks to strong respiratory and vaccine sales

Key Q3 drivers include Shingrix vaccine and asthma drug Nucala

- PMLiVE

GSK takes new-class antibiotic into phase 3 for serious infections

Could provide a much-needed option for treatment-resistant infections

- PMLiVE

GSK gets FDA okay for wider use of PARP drug Zejula

New approval should help it gain some ground from AZ's rival Lynparza

- PMLiVE

CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

Initially received a negative opinion of the drug

- PMLiVE

Merck wins CHMP recommendation for Ebola vaccine

Has also been granted priority review by FDA

- PMLiVE

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

New data in ovarian cancer creates potential for market battle

- PMLiVE

GSK and Apotex join generic Zantac recalls as carcinogen concerns mount

Novartis’ generic unit Sandoz halted distribution last week

EU flag

GW Pharma’s Epidyolex gets EU approval for severe epilepsy

Company is confident it can overturn preliminary 'no' from NICE

- PMLiVE

Astellas’ Xospata scores positive CHMP recommendation

Could become a potential option for hard-to-treat leukaemia

- PMLiVE

GSK to develop Ionis hepatitis B drugs

Competing with rivals Gilead to find cure for 200 million people

- PMLiVE

GSK preps filings for BCMA-targeting multiple myeloma drug

On course to file before end of year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links